| Abstract | A 7-year nationwide study of bromocriptine monotherapy and combination therapy with bromocriptine and levodopa in Parkinson's disease is reported. Of 22 patients who had been on bromocriptine monotherapy for 7 years (group B), 16 remained improved or remained in the same stages of Hoehn and Yahr, and no wearing-off phenomenon or dyskinesia was observed. In another 56 patients who were started on bromocriptine alone, but in whom combination therapy with levodopa was instituted at some time in the 7 years (group BL), disease progressed faster than in group B. A wearing-off phenomenon and dyskinesia occurred in 34% and 5.4% of the patients, respectively. These manifestations appeared only after initiation of levodopa. The favorable course of group B suggests possible neuroprotective effects of bromocriptine or may be due to the inevitable selection of patients who had a favorable course originally. |
| Authors | N Yanagisawa, I Kanazawa, I Goto, H Kowa, S Kuno, Y Mizuno, K Tashiro, N Ogawa
(Affiliation: Department of Medicine (Neurology), Shinshu University School of Medicine, Matsumoto, Japan.)
|
| Journal | European neurology
(Eur Neurol)
Vol. 34 Suppl 3
Pg. 29-35
( 1994)
ISSN: 0014-3022 SWITZERLAND |
| PMID | 7821333
(Publication Type: Journal Article)
|
| Chemical References |
|
| Topics |
- Adult
- Aged
- Bromocriptine
(administration & dosage, adverse effects)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Levodopa
(administration & dosage, adverse effects)
- Long-Term Care
- Male
- Middle Aged
- Neurologic Examination
(drug effects)
- Neurons
(drug effects)
- Parkinson Disease
(drug therapy)
- Substantia Nigra
(drug effects)
|
